78 results about "Neoplasm" patented technology

The present application discloses substituted polycyclic heterocycles compound of Formula (I), pharmaceutically acceptable salt and / or solvate and pharmaceutical compositions thereof useful in the treatment of proliferative disease or condition characterized by a dysregulation of the RAS-ERK pathway such as neoplasm disease or disorder, inflammatory disease or immune system disorder.

The invention relates to a Kluyveromyces marxianus strain with high protein yield and application of the Kluyveromyces marxianus strain, which is characterized in that the Kluyveromyces marxianus strain is firstly cultured on a slant, then is transferred into a seed culture medium for seed preparation, and then is inoculated into a fermentation tank, and yeast protein is obtained by adopting index feeding; the bacterial strain is a dominant mutant strain Kluyveromyces marxianus YWX-1, the protein content in a dry thallus reaches 55% or above and is increased by 26% or above compared with that of an original bacterial strain, the bacterial strain can be used for production of single-cell protein, the essential amino acid index (EAAI) value in the protein reaches 1.2, and the bacterial strain is rich in arginine, threonine and lysine and can be applied to production of single-cell protein. These amino acids play a key role in immune regulation, intestinal mucosal barrier function and muscle protein synthesis of young animals. The YWX-1 kluyveromyces marxianus strain has a wide application prospect in the production of neoplasm protein.

The wart-shaped neoplasm cutter and the wart-shaped neoplasm cutting and collecting integrated device comprise a fixed handle and a rotating handle, an installation space of a wart body collecting structure is reserved between the fixed handle and the rotating handle, a wart body cutting structure is arranged on the lower section of the fixed handle, and the wart body cutting structure is in mechanical linkage with the lower section of the rotating handle. The wart collecting structure is used for cutting off warts along with rotation of the rotating handle, and after the warts are cut off, the rotating handle can trigger the wart collecting structure through the triggering element on the upper section to complete collection of the cut warts at the same time. The utility model aims to solve the problems of inconvenience in treatment and cross infection risk after resection of neoplasm verrucosa in the prior art. Specifically, by means of the ingenious design, efficient cutting and instant collection of wart-shaped neoplasm are achieved, the operation process is simplified, safety is improved, and medical staff can conveniently and rapidly transfer collected wart samples to a laboratory for pathological examination.

Small molecules compounds and methods of their synthesis are provided. Small molecules identified can inhibit histone acetyltransferase 1 activity. Formulations and medicaments are also provided that are directed to the treatment of human disorders and conditions, such as, for example, neoplasms, cancers, viral, fungal, and parasitic infections, and aging. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.

Therapeutic compositions comprising chitosan-derived compositions are useful agents when administered in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.

Methods, systems, and apparatuses, including computer programs for detecting pancreatic neoplasms. A method includes providing an image as an input to a first model, obtaining first output data generated by the first model based on the first model's processing of the image, the first output data representing a portion of the image that depicts a pancreas, providing the first output data as an input to a second model, obtaining second output data generated by the second model based on the second model's processing of the second input data, the second output indicating whether the depicted pancreas is normal or abnormal, providing the first output data and the second output data as an input to a third model, and obtaining third output data generated by the third model, the third output data including data indicating that the pancreas is normal or data indicating a likely location of a pancreatic neoplasm.

This disclosure relates to a method for detecting colorectal cancer. The method comprises determining whether an advanced neoplasm is present in a first screening time period and upon determining that an advanced neoplasm is present in the first screening time period, performing colonoscopy in a second screening time period, after the first screening time period, to detect colorectal cancer. There is further provided a method for stratification of a subject comprising upon detection of an advanced neoplasm in a first screening time period, stratifying the subject into a high risk stratification for developing colorectal cancer in a second screening time period. There is further provided a computer implemented method for calculating a risk score for developing colorectal cancer comprising determining patient data; applying a trained machine learning model to the patient data to determine the risk score; and outputting the risk score.

Processes and materials to detect neoplasms from a biopsy are described. Processes and materials to build a sequencing library are described. Processes and material to perform targeted sequencing are described. Processes and materials to mitigate confounding sources are described. Cell-free nucleic acids can be sequenced and the sequencing result can be utilized to detect sequences derived from a neoplasm.

The present disclosure describes the use of an anti-insulin receptor antibody to treat neoplasms and / or tumor-associated hyperinsulinism and resulting hypoglycemia caused by benign or malignant neoplastic production of insulin and / or other effector substances (e.g., IGF-2 or its variants) that interact with the INSR and thus result in insulin-like action.

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases in a subject, wherein the proliferative diseases include cancer, benign neoplasm, angiogenesis, inflammatory disease, autoinflammatory disease, and autoimmune disease, and the cancer includes leukemia, melanoma, multiple myeloma. Treatment of a subject having a proliferative disease with the compounds or compositions of the present invention can inhibit abnormal activity of cyclin-dependent kinase 7, thus inducing apoptosis and / or inhibiting transcription in the subject.

Crystalline forms, including salts and polymorphs, of a compound useful in the treatment of tetracycline compound-responsive states are provided herein. The crystalline compounds are useful for the treatment or prevention of conditions and disorders such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds in general.

Processes and materials to detect cancer, transplant rejection, or fetal genetic abnormalities from a biopsy are described. In some cases, cell-free nucleic acids can be sequenced, and the sequencing result can be utilized to detect sequences indicative of a neoplasm, transplant rejection, or fetal genetic abnormality. Detection of somatic variants occurring in phase and / or insertions and deletions (indels) can indicate the presence of cancer, transplant rejection, or fetal genetic abnormalities in a diagnostic scan, and a clinical intervention can be performed.

The present disclosure relates to the use of compound (I) and any of its salts for the treatment of a neoplasm characterized by high expression of toll-like receptor 4 (TLR4) in the tumor or its microenvironment, associated with at least one of the pathophysiological complications including immunosuppression, angiogenesis, fibrosis, or metastasis.

Processes and materials to detect cancer from a biopsy are described. In some cases, cell-free nucleic acids can be sequenced, and the sequencing result can be utilized to detect sequences derived from a neoplasm. Detection of somatic variants occurring in phase can indicate the presence of cancer in a diagnostic scan and a clinical intervention can be performed.

The present invention relates to systems and methods for classification of cancer from gene expression input data. The method including: receiving a training dataset including nucleic acid data points from one or more samples; identifying classes in the training dataset including performing recursive clustering by, at each successive iteration, performing a search to identify clusters based on similarity, wherein each class of the classes is associated with a tumor; training a machine learning model to associate the nucleic acid data points of the training dataset with the identified classes; receiving the gene expression input data for classification; classifying, using the trained machine learning model, the gene expression input data as one or more of the identified classes; and outputting the classification of the gene expression input data.

The present disclosure provides a method for the treatment of neoplastic disease in a mammalian subject the method comprising the administration of an IL-10 agent in combination with the administration of at least one modulator of at least one immune checkpoint pathway. The present disclosure further provides a method for the treatment of neoplastic disease wherein the neoplasm has a low or intermediate tumor mutation burden, low or intermediate level of expression of the immune checkpoint molecule, or metastatic neoplastic disease.

Disclosed are methods of treatment, compositions and kits comprising endocannabinoid receptor (ECR) antagonist and an mTOR inhibitor for treating neoplasm in a subject in need thereof, and reducing drug resistance to standard treatment.

The present invention relates to agents for the treatment and / or diagnosis of endometriosis and other benign gynecological neoplasms disease or disorder and also relates to agents capable of eliciting a cytotoxic response in benign gynecological neoplasms diseases or disorders.

The present invention relates to novel and stable preparations of bacterial extracts that exhibit considerably greater stability over time, to new methods of preparing them, to pharmaceutical formulations based on these new stabilized bacterial extracts, as well as to new routes of administration and delivery devices for the treatment and / or prevention of acute and chronic immunological disorders resulting from infections, inflammation, neoplasms, or dysbiosis.

The present invention provides a bispecific antibody comprising one or more antigen-binding domains binding specifically to AXL antigen, and one or more antigen- binding domains binding specifically to PD-L1 antigen, the binding of which to AXL and / or PD-L1 antigen leads to its internalisation, as well as an antigen-binding fragment thereof binding specifically to AXL and / or PD-L1. The present invention provides also a nucleic acid encoding such a bispecific antibody, or antigen-binding fragment thereof, an antibody-drug conjugate comprising such a bispecific antibody, or antigen-binding fragment thereof, and a pharmaceutical composition comprising such a bispecific antibody, or antigen-binding fragment thereof, or such an antibody-drug conjugate, and a pharmaceutically acceptable excipient or carrier. Further, the present invention provides such a bispecific antibody or such a conjugate or such a pharmaceutical composition for use in therapy, for use in the therapy of a neoplasm, in particular a malignant neoplasm, particularly a neoplasm exhibiting surface expression of AXL and / or PD-L1. The invention provides also a method of treating or preventing neoplasm or its metastasis in an individual and a method of stimulating an immune response, comprising administering such a bispecific antibody, fragment, conjugate or pharmaceutical composition to the individual.

Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as gastric cancer.

The invention relates to cannabidiol-based (CBD) formulations, and to their use in treating, preventing or alleviating pain, inflammation, an autoimmune disease, a neurological disease, neoplasm, or nausea in a subject. The invention also concerns low-dose CBD compositions, and extends to their use in methods of treatment.

Disclosed are compositions comprising delta-tocotrienol and methods for using the same in the prevention of cancer progression. The methods comprise of reducing, inhibiting, decreasing, and / or preventing the progression of a neoplasm to a cancer (including, but not limited to lung cancer, ovarian cancer, breast cancer, rectal cancer, pancreatic, colon cancer, or intraductal papillary mucinous neoplasm (IPMN) to pancreatic ductal adenocarcinoma) in a subject comprising administering to a subject a therapeutically effective amount of a composition comprising delta-tocotrienol (d-T3).

Composition and methods for immunotherapy of a cancer patient, comprising administering a black seed oil composition or one or more components thereof, which can include thymoquinone, oleic acid, linoleic acid, palmitic acid, eicosapentaenoic acid, or docosahexaenoic acid. The composition or components can be administered in combination with one or more immune checkpoint inhibitors, including anti-CLA-4 agents and anti-PD-1 agents. The cancers targeted by the compositions and combinations include neuroendocrine cancers, and, in particular, high grade neoplasms and poorly differentiated neuroendocrine carcinomas, including advanced or metastatic neuroendocrine carcinomas and, more particularly, refractory advanced or metastatic gastroenteropancreatic neuroendocrine carcinomas.

The present invention relates to novel stable bacterial extract preparations having substantial increased stability overtime, novel methods of preparation thereof, pharmaceutical formulations based on these novel stabilized bacterial extracts, as well as novel routes of administration and delivery devices for treating and / or preventing acute and chronic immunological disorders resulting from infections and / or inflammation and / or neoplasms and / or dysbiosis.

The present invention relates to novel compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, a medicinal use thereof, and a method for preparing the same. The novel compounds according to the present invention, stereoisomers thereof or pharmaceutically acceptable salts thereof have the histone deacetylase 6 (HDAC6) inhibitory activity, and are effective in preventing or treating HDAC6-related diseases, comprising infectious diseases; neoplasm; endocrinopathy; nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; eye and ocular adnexal diseases; circulatory diseases; respiratory diseases; digestive diseases; skin and subcutaneous tissue diseases; musculoskeletal system and connective tissue diseases; and teratosis or deformities, or chromosomal aberration.

The present disclosure provides T cell receptors (TCRs) that bind to COL6A3 and their use in medical treatment or prophylaxis, for example the treatment of COL6A3-expressing neoplasms or cancers. The present disclosure also provides nucleic acids and expression vectors that encode the TCRs.

The present invention relates to pharmaceutical agents useful for therapy and / or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin / MLL protein / protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia, myelodysplastic syndrome (MDS), and myeloproiiferative neoplasms (MPN); and diabetes.

Provided herein are methods for treating a brachyury-associated cancer or neoplasm, e.g., chordoma, with a type I interferon in a subject in need thereof. The methods further include treating the brachyury-associated cancer or neoplasm with interferon alpha or interferon beta by injection of interferon protein into a subject in need thereof, wherein the interferon can be an interferon polypeptide or an interferon nucleic acid formulated for expression.

This disclosure relates to antibodies and derivatives that bind the full-length isoform of aspartate beta-hydroxylase (ASPH) and uses thereof. The antibodies and derivatives are useful in compositions and methods for detecting and / or treating a malignant neoplasm in a subject and for predicting subsequent complications of untreated progression of the malignant neoplasm in the subject.